Everest Medicines Ltd. (HK:1952)
:1952
Top Page
Everest Medicines Ltd.
(1952)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$41.00
▼(-20.39% Downside)
Action:ReiteratedDate:04/02/26
The score is held back primarily by continued losses and negative free cash flow, despite major improvement in cash burn and strong revenue growth with healthy gross margins. Technicals are moderately constructive in the near term (above 20/50-day averages with RSI ~60) but weaker on a longer-term basis (below the 200-day average). Valuation remains challenged because the company is loss-making and provides no dividend yield.
Positive Factors
Rapid Revenue Growth
Nearly 95% top-line growth in 2025 signals rapid commercial traction and expanding market penetration. Sustained revenue expansion improves the odds of achieving scale, spreads fixed costs, enhances unit economics, and provides a firmer base to fund R&D and commercialization over the medium term.
Negative Factors
Ongoing Unprofitability
Net margin around -17% in 2025 shows the business is still loss-making despite revenue growth. Persistent losses erode capital over time, restrict internal reinvestment, and require management to balance growth spending with the need to move toward sustainable profitability to preserve shareholder value.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Nearly 95% top-line growth in 2025 signals rapid commercial traction and expanding market penetration. Sustained revenue expansion improves the odds of achieving scale, spreads fixed costs, enhances unit economics, and provides a firmer base to fund R&D and commercialization over the medium term.
Read all positive factors
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$14.43B
Dividend YieldN/A
Average Volume (3M)3.13M
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth102.73%
EPS Growth38.42%
CountryHK
Employees665
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding353,581,150
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)2.11
Price to Sales (P/S)6.72
P/FCF Ratio-64.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.63
Revenue Forecast (FY)HK$3.32B
Everest Medicines Ltd. Business Overview & Revenue Model
Company Description
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline...
How the Company Makes Money
null...
Everest Medicines Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 851.28M | 1.66B | 706.68M | 125.93M | 12.79M | 54.00K |
| Gross Profit | 597.21M | 998.84M | 528.89M | 91.52M | 8.15M | 31.00K |
| EBITDA | -276.68M | -223.85M | -670.04M | -744.63M | -198.91M | -972.78M |
| Net Income | -658.75M | -290.06M | -1.04B | -844.46M | -247.28M | -1.01B |
Balance Sheet | ||||||
| Total Assets | 4.93B | 6.84B | 4.96B | 5.77B | 6.61B | 6.65B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 2.73B | 1.60B | 2.35B | 1.65B | 2.64B |
| Total Debt | 708.72M | 925.98M | 575.61M | 510.63M | 534.64M | 485.03M |
| Total Liabilities | 1.01B | 1.53B | 886.05M | 804.10M | 960.25M | 753.83M |
| Stockholders Equity | 3.93B | 5.31B | 4.07B | 4.97B | 5.65B | 5.89B |
Cash Flow | ||||||
| Free Cash Flow | -205.84M | -172.32M | -744.92M | -1.04B | -1.59B | -1.71B |
| Operating Cash Flow | -181.47M | -109.96M | -679.51M | -769.19M | -1.16B | -729.94M |
| Investing Cash Flow | 423.71M | -674.78M | 974.40M | 752.50M | -1.03B | -975.82M |
| Financing Cash Flow | 171.64M | 1.75B | 37.80M | 10.10M | -25.31M | -76.51M |
Everest Medicines Ltd. Technical Analysis
Neutral
51.50
Price Trends
37.76
Positive
40.80
Negative
51.01
Negative
Market Momentum
0.36
Negative
60.87
Neutral
86.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1952, the sentiment is Neutral. The current price of 51.5 is above the 20-day moving average (MA) of 36.58, above the 50-day MA of 37.76, and above the 200-day MA of 51.01, indicating a neutral trend. The MACD of 0.36 indicates Negative momentum. The RSI at 60.87 is Neutral, neither overbought nor oversold. The STOCH value of 86.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1952.
Everest Medicines Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$23.20B | 31.11 | -3.42% | ― | 58.24% | 38.85% | |
64 Neutral | HK$9.37B | 20.83 | 4.47% | 4.28% | -8.49% | -9.46% | |
53 Neutral | HK$14.43B | -38.53 | -11.43% | ― | 102.73% | 38.42% | |
53 Neutral | HK$10.63B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$20.03B | -25.84 | -17.26% | ― | 964.40% | 65.90% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:1952
Everest Medicines Ltd.
40.80
-4.30
-9.53%
HK:9969
InnoCare Pharma Ltd.
15.52
7.86
102.61%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2162
Keymed Biosciences, Inc.
71.35
32.70
84.61%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.39
7.51
69.03%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.24
0.75
3.49%
Everest Medicines Ltd. Corporate Events
Everest Medicines Honorary Chairman Boosts Stake in Company
Mar 30, 2026
Everest Medicines Limited has disclosed that non-executive director and honorary chairman Wei Fu, also a substantial shareholder, increased his stake in the company. Acting through a controlled entity, Fu bought 860,000 shares on the open market o...
Everest Medicines Publishes Audited 2025 Annual Results and Report
Mar 25, 2026
Everest Medicines Limited has released its audited annual results for the year ended 31 December 2025, confirming that the full 2025 annual report is now available in both Chinese and English. The results, reviewed by the audit committee and Ernst...
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
Mar 23, 2026
Everest Medicines has agreed, through a wholly owned subsidiary, to acquire specific intellectual property and inventory related to a cardiovascular product from an independent third-party seller under an asset purchase agreement valued at up to U...
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
Mar 17, 2026
Everest Medicines has signed a letter of intent with Hasten Biopharmaceuticals (Asia) Limited to potentially acquire the entire equity interest in Hasten Biopharmaceuticals (SG) Pte. Ltd., which holds commercial rights to 14 branded chronic diseas...
Everest Medicines Sets March 2026 Board Meeting to Approve 2025 Annual Results
Mar 10, 2026
Everest Medicines has scheduled a board meeting for 25 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The meeting will also address any other board business, signaling the start of ...
Everest Medicines Shareholders Approve Commercial Pact and New 2026 Equity Incentive Scheme
Feb 24, 2026
Everest Medicines shareholders approved all resolutions at an extraordinary general meeting held virtually on 24 February 2026, including ratification of a Commercialization Service Agreement and a grant of 530,303 awards to executive director Yif...
Everest Medicines Wins China Approval for Ulcerative Colitis Drug VELSIPITY and Outlines Ambitious 2030 Growth Plan
Feb 6, 2026
Everest Medicines has received approval from China’s National Medical Products Administration for VELSIPITY (etrasimod arginine tablets), an oral, once-daily selective S1P receptor modulator for adults with moderately to severely active ulce...
Everest Medicines Secures Exclusive Asian Rights to First-in-Class SHPT Drug MT1013
Feb 4, 2026
Everest Medicines’ China subsidiary has entered into an exclusive licensing agreement with Shaanxi Micot Pharmaceutical Technology to commercialize MT1013, a first-in-class dual-targeting receptor agonist for secondary hyperparathyroidism, a...
Everest Medicines Calls Virtual EGM to Approve Commercial Deal and New Share Incentive Plan
Feb 3, 2026
Everest Medicines Limited has called an extraordinary general meeting for 24 February 2026, to be held virtually, at which shareholders will vote on approving and ratifying a commercialization service agreement between its China subsidiary and Has...
Everest Medicines Sets February 2026 Date and Book Closure for Extraordinary General Meeting
Feb 2, 2026
Everest Medicines Limited has scheduled an extraordinary general meeting (EGM) for 24 February 2026, setting the same date as the record date to determine shareholders’ eligibility to attend and vote. To facilitate this, the company will clo...
Everest Medicines Signs Connected Lease for Expanded Shanghai R&D and Production Site
Jan 26, 2026
Everest Medicines has entered into a connected lease transaction through a subsidiary with Kang Pu for approximately 11,459 square metres of space in Building 8 of Kangpu Life Science Industrial Park in Shanghai’s Qingpu District, to be used...
Everest Medicines Delays Shareholder Circular on Commercialization Service Agreement
Jan 16, 2026
Everest Medicines Limited has announced a delay in sending a shareholder circular relating to its continuing connected transactions under a Commercialization Service Agreement. The circular, which will include details of the agreement, recommendat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.